Briefly Bio Secures $1.2M Funding for Lab Innovation
Briefly Bio, a London, UK-based techbio startup, recently secured $1.2M in funding in a round led by Compound VC, with participation from NP Hard and Tiny VC. The company, founded by Dr Katya Putintseva, Harry Rickerby and Staffan Piledahl, aims to provide a tool to make lab work more reproducible. With this new injection of capital, Briefly Bio plans to expand its operations and further develop its innovative software platform.
The tool developed by Briefly Bio enables scientists to capture and share their experiments in a clear and consistent manner.
By utilizing AI technology, the software helps to convert existing experiment descriptions into a standardized format, while also identifying and correcting any errors or missing information. This not only enhances the reproducibility of lab work, but also facilitates knowledge sharing among researchers, allowing them to learn from one another's work.
The funding round led by Compound VC, NP Hard, and Tiny VC reflects the confidence that investors have in Briefly Bio's mission and technology. As the company continues to make strides in the techbio industry, it is poised to become a valuable resource for scientists looking to improve the rigor and reliability of their research. With a strong team of founders at the helm, including Dr Katya Putintseva, Harry Rickerby, and Staffan Piledahl, Briefly Bio is well-positioned for success in the competitive field of lab work reproducibility.
They've invested in Briefly Bio
Get to know these AI investors
Click here for a full list of 6,528+ startup investors in the UK